Sanuwave Health (NASDAQ:SNWV) Announces Quarterly Earnings Results, Misses Estimates By $0.14 EPS

Sanuwave Health (NASDAQ:SNWV) announced its quarterly earnings data on Thursday. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.17 by ($0.14), FiscalAI reports. The business had revenue of $13.09 million during the quarter, compared to analyst estimates of $13.23 million.

Sanuwave Health Trading Down 5.4%

Shares of SNWV stock traded down $1.08 during trading on Thursday, reaching $18.85. 153,648 shares of the company’s stock traded hands, compared to its average volume of 59,937. The firm’s 50-day moving average is $24.37 and its 200 day moving average is $29.62. The company has a market capitalization of $161.73 million, a P/E ratio of -14.50 and a beta of 1.32. Sanuwave Health has a 1 year low of $18.61 and a 1 year high of $46.58.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Praetorian PR LLC grew its holdings in Sanuwave Health by 1,436.2% during the 4th quarter. Praetorian PR LLC now owns 265,000 shares of the company’s stock valued at $7,908,000 after buying an additional 247,750 shares in the last quarter. Stifel Financial Corp purchased a new stake in shares of Sanuwave Health in the fourth quarter worth about $5,291,000. Geode Capital Management LLC purchased a new stake in shares of Sanuwave Health in the second quarter worth about $5,184,000. Lazard Asset Management LLC bought a new position in shares of Sanuwave Health in the second quarter valued at approximately $738,000. Finally, Jane Street Group LLC bought a new position in shares of Sanuwave Health in the fourth quarter valued at approximately $587,000. Institutional investors own 42.53% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sanuwave Health in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Sanuwave Health currently has a consensus rating of “Moderate Buy” and a consensus target price of $54.00.

About Sanuwave Health

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.